Ren Yu, Huang Weiping, Weng Guobin, Cui Pinger, Liang Haote, Li Yeping
Department of Urology, Ningbo Urology and Nephrology Hospital, Ningbo 315000, Zhejiang Province, People's Republic of China.
Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, People's Republic of China,
Onco Targets Ther. 2019 Apr 5;12:2563-2575. doi: 10.2147/OTT.S190239. eCollection 2019.
LncRNAs have recently emerged as vital regulators in the pathogenesis and development of various cancers. LncRNA PVT1 is reported to function as an oncogene in some tumors. However, the role of PVT1 in RCC remains unknown.
To explore the potential effects of lncPVT1 on the development of renal cell carcinoma.
The expression of PVT1 in renal cancer cell lines and tissues was measured by qRT-PCR. The endogenous PVT1 was silenced by RNAi. Cell viabilities were measured by the MTT assay. The migration and invasion of cells were investigated by the transwell assay. The apoptosis of cells was measured by the Nucleosome ELISA and caspase-3 activity assays. The levels of proteins were measured by the western blot.
We found that PVT1 was upregulated in RCC tissues compared with the adjacent normal tissues. PVT1 expression was closely correlated with TNM stage, Fuhrman grade, lymph node metastasis and tumor size. Kaplan-Meier analysis revealed that high expression of PVT1 was significantly associated with poor overall survival. In accordance, overexpression of PVT1 was observed in RCC cells comto HK-2 cell. Silencing of PVT1 significantly repressed cell viability, induced apoptosis and inhibited cell migration and invasion in vitro. Furthermore, bioinformatic analysis and luciferase reporter assay confirmed that miR-16-5p was a target of PVT1. Silencing of miR-16-5p mostly reversed the regulatory effects on RCC cells induced by downregulation of PVT1.
In summary, our study indicates that targeting PVT1 might represent a rational therapeutic strategy for RCC.
长链非编码RNA(lncRNAs)最近已成为各种癌症发病机制和发展中的重要调节因子。据报道,lncRNA PVT1在某些肿瘤中发挥癌基因的作用。然而,PVT1在肾细胞癌(RCC)中的作用仍不清楚。
探讨lncPVT1对肾细胞癌发展的潜在影响。
通过qRT-PCR检测PVT1在肾癌细胞系和组织中的表达。通过RNA干扰使内源性PVT1沉默。通过MTT法检测细胞活力。通过Transwell法研究细胞的迁移和侵袭。通过核小体ELISA和caspase-3活性测定法检测细胞凋亡。通过蛋白质印迹法检测蛋白质水平。
我们发现与相邻正常组织相比,PVT1在RCC组织中上调。PVT1表达与TNM分期、Fuhrman分级、淋巴结转移和肿瘤大小密切相关。Kaplan-Meier分析显示,PVT1的高表达与总体生存率差显著相关。相应地,在RCC细胞中观察到PVT1的过表达,相对于HK-2细胞。PVT1的沉默显著抑制细胞活力,诱导细胞凋亡,并在体外抑制细胞迁移和侵袭。此外,生物信息学分析和荧光素酶报告基因测定证实miR-16-5p是PVT1的靶标。miR-16-5p的沉默大多逆转了PVT1下调对RCC细胞的调节作用。
总之,我们的研究表明靶向PVT1可能是RCC的一种合理治疗策略。